• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[终末期慢性肾功能不全患者当前治疗的某些方面]

[Some aspects of current treatment of patients with terminal chronic renal insufficiency].

作者信息

Burtsev V I, Grankin V I, Briukhovetskiĭ A G, Klopotskiĭ S A, Miasnikova E B

出版信息

Klin Med (Mosk). 1993 Jan;71(1):33-6.

PMID:8046902
Abstract

Two groups of patients with terminal chronic renal failure (TCRF) treated from 1970 to 1979 (group 1) and in 1980-1989 (group 2) have been compared in respect to treatment results. All the patients underwent programmed hemodialysis performed on different equipment and according to different regimens. The results of group 2 appeared better: the lethality decreased by 18%, mean survival from 6 months to 4.5 years, up to half of the patients were able to receive hemodialysis procedures outpatiently, 30% of the patients were prepared to receive a renal transplant. The above positive shifts were achieved due to utilization of updated equipment, improved water purification, 3-stage technique of hemodialysis, antianemic drug eprex and vanalpha against osteodystrophy.

摘要

对1970年至1979年(第1组)以及1980年至1989年(第2组)接受治疗的两组终末期慢性肾衰竭(TCRF)患者的治疗结果进行了比较。所有患者均按照不同方案在不同设备上进行了计划性血液透析。第2组的结果更好:死亡率降低了18%,平均生存期从6个月延长至4.5年,多达一半的患者能够在门诊接受血液透析治疗,30%的患者准备接受肾移植。上述积极变化得益于采用了更新的设备、改进了水净化、采用了三阶段血液透析技术、使用了抗贫血药物依泊汀以及使用了防治骨营养不良的药物万阿法。

相似文献

1
[Some aspects of current treatment of patients with terminal chronic renal insufficiency].[终末期慢性肾功能不全患者当前治疗的某些方面]
Klin Med (Mosk). 1993 Jan;71(1):33-6.
2
[The efficacy of an erythropoietin-calcitriol combination in patients with chronic kidney failure on programmed hemodialysis].
Ter Arkh. 1995;67(5):27-31.
3
[The use of recombinant erythropoietin with patients on programmed hemodialysis].
Ter Arkh. 1991;63(12):110-3.
4
Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.血液透析患者和肾移植受者的血清促红细胞生成素水平及其与红细胞生成系统的相关性。
Transplant Proc. 2007 May;39(4):1051-3. doi: 10.1016/j.transproceed.2007.03.048.
5
Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis.影响选择不接受透析的晚期慢性肾病患者生存的因素。
Ren Fail. 2007;29(6):653-9. doi: 10.1080/08860220701459634.
6
[Transplantation of the kidney--optimal treatment of patients suffering from diabetes mellitus type 1 with terminal chronic renal failure].[肾脏移植——1型糖尿病合并终末期慢性肾衰竭患者的最佳治疗方法]
Ter Arkh. 2007;79(6):40-4.
7
[Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].[去铁胺对接受促红细胞生成素治疗的慢性肾功能不全血液透析患者红细胞生成的影响]
Pol Merkur Lekarski. 1996 Oct;1(4):232-4.
8
Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group.接受重组人促红细胞生成素治疗的血液透析患者生活质量和功能能力的变化。加拿大促红细胞生成素研究组。
Semin Nephrol. 1990 Mar;10(2 Suppl 1):11-9.
9
Results of the Canadian morbidity study in end-stage renal disease patients treated by hemodialysis.
Semin Nephrol. 1990 Mar;10(2 Suppl 1):66-72.
10
[The effect of recombinant human erythropoietin during hemodialysis on the thrombocyte and erythrocyte functions of patients with chronic kidney failure].重组人促红细胞生成素在血液透析期间对慢性肾衰竭患者血小板及红细胞功能的影响
Ter Arkh. 1994;66(6):57-60.